lg 100268 has been researched along with Compensatory Hyperinsulinemia in 2 studies
LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source
Compensatory Hyperinsulinemia: A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To determine whether rexinoids lower hyperglycemia by activating the RXR/PPAR-gamma heterodimer in vivo, we compared the effects of a rexinoid (LG100268) and a TZD (rosiglitazone) on gene expression in white adipose tissue, skeletal muscle, and liver of Zucker diabetic fatty rats (ZDFs)." | 3.71 | Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. ( Boehm, M; Crombie, DL; Davies, PJ; Depre, C; Heyman, RA; Leibowitz, MD; Liu, S; Nagy, L; Singh Ahuja, H; Tontonoz, P, 2001) |
| "peroxisome accumulation and hepatomegaly) than PPARgamma agonists." | 1.30 | The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. ( Binz, JG; Brown, HR; Gaskill, BA; Lancaster, ME; Lenhard, JM; Lightfoot, RM; Paulik, MA; Sundseth, SS; Weiel, JE, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lenhard, JM | 1 |
| Lancaster, ME | 1 |
| Paulik, MA | 1 |
| Weiel, JE | 1 |
| Binz, JG | 1 |
| Sundseth, SS | 1 |
| Gaskill, BA | 1 |
| Lightfoot, RM | 1 |
| Brown, HR | 1 |
| Singh Ahuja, H | 1 |
| Liu, S | 1 |
| Crombie, DL | 1 |
| Boehm, M | 1 |
| Leibowitz, MD | 1 |
| Heyman, RA | 1 |
| Depre, C | 1 |
| Nagy, L | 1 |
| Tontonoz, P | 1 |
| Davies, PJ | 1 |
2 other studies available for lg 100268 and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction.
Topics: Animals; Blood Glucose; Cachexia; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 1999 |
Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease | 2001 |